In patients suffering from EGPA, the add-on treatment with anti-IL5/IL-5r monoclonal antibodies provides a consistent clinical and functional improvement, allows corticosteroid tapering and favors the achievement of EGPA remission (26–28). This evidence concerns the gene IL5RA and eosinophilic granulomatosis with polyangiitis.